Mupirocin Calcium Salt Dihydrate
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-03981 |
| CAS | 115074-43-6 |
| Molecular Weight | 538.68 |
| Molecular Formula | C26H44O9.1/2Ca.H2O |
| Purity | 98% |
Online Inquiry
Description
A carboxylic acid bacteriostatic/bactericidal antibiotic. Mupirocin Calcium Salt sodium is a calcium salt of Mupirocin, which is a carboxylic acid bacteriostatic/bactericidal antibiotic.
Specification
| Related CAS | 12650-69-0 (free acid) 73346-79-9 (lithium) 104486-81-9 (anhydrous) |
| Synonyms | [2E,8[2S,3S(1S,2S)]]-5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-L-talo-Non-2-enonic Acid 8-Carboxyoctyl Ester Calcium Salt Dihydrate; Calcium Mupirocin Dihydrate; Mupirocin Calcium Hydrate |
| Storage | Store at -20°C, Under inert atmosphere |
| IUPAC Name | calcium;9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoate;dihydrate |
| Canonical SMILES | CC(C1C(O1)CC2COC(C(C2O)O)CC(=CC(=O)OCCCCCCCCC(=O)[O-])C)C(C)O.CC(C1C(O1)CC2COC(C(C2O)O)CC(=CC(=O)OCCCCCCCCC(=O)[O-])C)C(C)O.O.O.[Ca+2] |
| InChI | InChI=1S/2C26H44O9.Ca.2H2O/c2*1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27;;;/h2*13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29);;2*1H2/q;;+2;;/p-2/b2*16-13+;;;/t2*17-,18-,19-,20-,21-,24+,25-,26-;;;/m00./s1 |
| InChI Key | DDHVILIIHBIMQU-YJGQQKNPSA-L |
Properties
| Appearance | White Solid |
| Application | Protein Synthesis Inhibitors |
| Melting Point | >126°C (dec.) |
| Solubility | Soluble in DMSO (Slightly), Methanol (Slightly) |
Reference Reading
1. Intranasal Mupirocin to Prevent Postoperative Staphylococcus aureus Infections
Perl, T.M., Cullen, J.J., Wenzel, R.P., Zimmerman, M.B., Pfaller, M.A., Sheppard, D., Twombley, J., French, P.P., Herwaldt, L.A. and Mupirocin and the Risk of Staphylococcus aureus Study Team, 2002. New England Journal of Medicine, 346(24), pp.1871-1877.
Patients with nasal carriage of Staphylococcus aureus have an increased risk of surgical-site infections caused by that organism. Treatment with mupirocin ointment can reduce the rate of nasal carriage and may prevent postoperative S. aureus infections.
2. Development of Mupirocin Resistance Among Methicillin-Resistant Staphylococcus aureus After Widespread Use of Nasal Mupirocin Ointment
Miller, M.A., Dascal, A., Portnoy, J. and Mendelson, J., 1996. Infection Control & Hospital Epidemiology, 17(12), pp.811-813.
All methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from colonized or infected patients in a 625-bed public teaching hospital during an epidemic, and for 3 years thereafter, underwent susceptibility testing to mupirocin. Mupirocin resistance among MRSA increased markedly over this period (1990, 2.7%; 1991, 8.0%; 1992, 61.5%; 1993, 65%) in association with increased use of mupirocin ointment as an adjunct to infection control measures.
Recommended Products
| BBF-03774 | Cephalosporin C Zinc Salt | Inquiry |
| BBF-05734 | Irofulven | Inquiry |
| BBF-01851 | Fumagillin | Inquiry |
| BBF-03881 | Sancycline | Inquiry |
| BBF-02800 | DB-2073 | Inquiry |
| BBF-03781 | Resveratrol | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
